Sclerosis MDPI

🧬 Why is systemic sclerosis still so difficult to diagnose and treat despite decades of research?

📚 A new review explores the complex pathophysiology of systemic sclerosis (SSc), highlighting how vascular dysfunction, immune dysregulation, and fibrosis interact to drive progressive organ damage. The paper also discusses emerging precision medicine strategies and future therapeutic directions.

📄 Pathophysiology in Systemic Sclerosis: Current Insights and Future Perspectives

✍️ Suzan Al-Gburi et al.

🔗 https://brnw.ch/21x2V1p

🩺 Special Issue: Recent Advances in Understanding Systemic Sclerosis
🔗 https://brnw.ch/21x2V1o

🎉 We are pleased to welcome a new Editorial Board Member to the journal!

👨‍⚕️ Prof. Dr. Minoru Hasegawa joins the Editorial Board, bringing extensive expertise in systemic sclerosis, rheumatic skin diseases, biomarkers, and translational disease models.

🏛️ Department of Dermatology, Faculty of Medical Sciences, University of Fukui, Japan

🤝 We look forward to Prof. Hasegawa’s valuable contributions to the journal and the research community.

🧬 Why is systemic sclerosis still so hard to diagnose early — and what if metabolism holds the missing clue?

🔍 This systematic review maps the metabolomic alterations in systemic sclerosis, revealing consistent disruptions in energy, lipid, amino acid, and mitochondrial pathways across studies — with potential links to fibrosis, vasculopathy, and organ involvement.

📄 The Metabolomic View of Systemic Sclerosis—A Systematic Literature Review

✍️ Sebastian T. Jendrek et al.

🔗 https://brnw.ch/21x2QPP

🧪 Special Issue: Recent Advances in Understanding Systemic Sclerosis
🔗 https://brnw.ch/21x2QPQ

⚠️ Systemic sclerosis is far more complex than skin fibrosis alone.

🧠 New research perspectives reveal a disease shaped by immune chaos, vascular damage, epigenetic rewiring, and organ-specific molecular signatures — with single-cell technologies now uncovering hidden pathways never seen before.

📄 The Evolving Landscape of Systemic Sclerosis Pathogenesis: From Foundational Mechanisms to Organ-Specific Modifiers

✍️ Toshiya Takahashi and Yoshihide Asano

🔗 https://brnw.ch/21x2OXy

📚 Special Issue: Recent Advances in Understanding Systemic Sclerosis
🔗 https://brnw.ch/21x2OXx

🚨 Exciting News! 🚨

🎉 We are thrilled to welcome Prof. Dr. Takashi Matsush*ta to our Editorial Board!

🧠 As an expert in dermatology at Kanazawa University, Prof. Matsush*ta’s research focuses on systemic sclerosis, dermatomyositis, autoantibodies, and B-cell biology.

🌍 His expertise will bring valuable perspectives and further strengthen our commitment to advancing high-quality research and innovation.

👏 Please join us in giving Prof. Matsush*ta a warm welcome!

🚨 Fatigue in multiple sclerosis isn’t just “feeling tired” — and this study shows why.

🚶 Researchers found that some people with mild MS experience measurable declines in walking speed, cadence, and step length during intermittent walking, even when traditional fatigue symptoms don’t fully explain the performance drop.

📄 Acute Effects of Intermittent Walking on Gait Parameters and Fatigability in People with Mild Multiple Sclerosis

✍️ Cintia Ramari et al.

🔗 https://brnw.ch/21x2N17

📚 Special Issue: Neuropsychiatric and Quality of Life (QoL) Aspects of Multiple Sclerosis, 2nd Edition
🔗 https://brnw.ch/21x2N16

⚠️ A patient may perform well in the clinic… and still face serious fall risks in daily life.

🚶‍♀️ Researchers showed that traditional mobility tests like the TUG may fail to capture the complexity of real-world movement in multiple sclerosis. Dual-task gait assessments delivered a more realistic picture of mobility — and a better warning system for falls.

📝 Beyond the Timed Up and Go: Dual-Task Gait Assessments Improve Fall Risk Detection and Reflect Real-World Mobility in Multiple Sclerosis

✍️ Michael VanNostrand et al.

🔗 https://brnw.ch/21x2FYt

🌐 Special Issue: Advances in Balance and Gait Assessment, Monitoring and Rehabilitation in Multiple Sclerosis
🔗 https://brnw.ch/21x2FYs

⚡ A simple walking test may reveal far more about multiple sclerosis progression than we think.

🚶 Researchers found a strong link between walking speed and self-reported disability in adults with MS — highlighting how objective movement data and patient experiences can work together to shape smarter interventions.

🧠 The study reinforces the growing importance of personalized rehabilitation and tele-exercise strategies tailored to real-world functional abilities.

📘 The Relationship Between Disability and Walking Speed in Adults with Multiple Sclerosis

✍️ Tracy Flemming-Tracy et al.

🔗 https://brnw.ch/21x2DWV

📈 A valuable step toward more individualized and patient-centered MS care.

The Relationship Between Disability and Walking Speed in Adults with Multiple Sclerosis Introduction: Timed Twenty-Five Foot Walk (T25FW) and Patient-Determined Disease Steps (PDDSs) are measures commonly used for people with MS (PwMS). However, there is limited knowledge about the utility of using the measures to customize interventions. Aim: This exploratory study aimed to assess the...

🧬 A microscopic injury to kidney podocytes can ultimately lead to life-changing kidney failure. Yet FSGS remains one of nephrology’s most complex and rapidly evolving diseases.

⚡ This state-of-the-art review dives into the rising global burden of FSGS, the growing role of APOL1 genetics, post-transplant recurrence challenges, and the next wave of targeted therapies reshaping kidney care.

📄 Focal and Segmental Glomerulosclerosis: A Comprehensive State-of-the-Art Review

✍️ Dearbhail Ni Cathain et al.

🔗 https://brnw.ch/21x2BKX

🫁 Are patients with systemic sclerosis developing progressive pulmonary fibrosis without being identified early enough?

📊 Real-world UK data revealed that 23% of patients with systemic sclerosis-related interstitial lung disease (SSc-ILD) developed progressive pulmonary fibrosis (PPF), with a median onset of 5 years. The study also found that only half of eligible patients were referred for consideration of anti-fibrotic therapy, highlighting important gaps in case finding and management.

📄 Identifying Patients with Systemic Sclerosis and Progressive Pulmonary Fibrosis in a Real-World Setting: Data from UK Tertiary Rheumatology and ILD Centres

✍️ Rosalind Benson et al.

🔗 Find out here: https://brnw.ch/21x2zIK

🌐 Special Issue: Advances and New Insights in Systemic Sclerosis
🔗 https://brnw.ch/21x2zIL

🏷️